Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Intrabone infusion for allogeneic umbilical cord blood transplantation in children

Abstract

Umbilical cord blood transplantation (UCBT) has been used to treat malignant and non-malignant diseases. UCBT offers the advantages of easy procurement and acceptable partial HLA mismatches, but also shows delayed hematopoietic and immunological recoveries. We postulated that an intrabone (IB) infusion of cord blood could provide a faster short- and long-term engraftment in a pediatric population with malignant and non-malignant hematologic diseases. We conducted this phase I-II single arm, exploratory clinical trial (NCT01711788) from 2012 to 2016 in a single center. Fifteen patients aged from 1.9 to 16.4 years received an IB UCBT. Median time to neutrophils and platelet recoveries were 18 days (range: 13-36 days) and 42 days (range: 26-107 days), respectively. Rate of severe acute GVH grade was low, with only one patient with grade III aGVH. Relapse occurred in 5 patients (38.5%) and TRM occurred in 1 patient. This leads to 6 years EFS and OS of 66.7% and 80% respectively. In conclusion, IB UCBT is safe and well-tolerated in children and hematological recovery compared similarly to the results obtained with IV UCBT.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Survival of the 15 patients included in the trial.

References

  1. 1.

    Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321:1174–8.

    CAS  Article  Google Scholar 

  2. 2.

    Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 1997;337:373–81.

    CAS  Article  Google Scholar 

  3. 3.

    Dessels C, Alessandrini M, Pepper MS. Factors influencing the umbilical cord blood stem cell industry: an evolving treatment landscape. Stem Cells Transl Med. 2018;7:643–50.

    Article  Google Scholar 

  4. 4.

    Mayani H, Wagner JE, Broxmeyer HE. Cord blood research, banking, and transplantation: achievements, challenges, and perspectives. Bone Marrow Transpl. 2020;55:48–61.

    Article  Google Scholar 

  5. 5.

    Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood. 2001;97:2962–71.

    CAS  Article  Google Scholar 

  6. 6.

    Eapen M, Rubinstein P, Zhang M-J, Stevens C, Kurtzberg J, Scaradavou A, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007;369:1947–54.

    Article  Google Scholar 

  7. 7.

    Locatelli F, Kabbara N, Ruggeri A, Ghavamzadeh A, Roberts I, Li CK, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood. 2013;122:1072–8.

    CAS  Article  Google Scholar 

  8. 8.

    Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N. Engl J Med. 2004;351:2276–85.

    CAS  Article  Google Scholar 

  9. 9.

    Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang M-J, Arcese W, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11:653–60.

    Article  Google Scholar 

  10. 10.

    Smith AR, Baker KS, Defor TE, Verneris MR, Wagner JE, Macmillan ML. Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors. Biol Blood Marrow Transpl. 2009;15:1086–93.

    Article  Google Scholar 

  11. 11.

    Keating AK, Langenhorst J, Wagner JE, Page KM, Veys P, Wynn RF, et al. The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia. Blood Adv. 2019;3:1118–28.

    CAS  Article  Google Scholar 

  12. 12.

    Merindol N, Charrier E, Duval M, Soudeyns H. Complementary and contrasting roles of NK cells and T cells in pediatric umbilical cord blood transplantation. J Leukoc Biol. 2011;90:49–60.

    CAS  Article  Google Scholar 

  13. 13.

    Lou X, Zhao C, Chen H. Unrelated donor umbilical cord blood transplant versus unrelated hematopoietic stem cell transplant in patients with acute leukemia: a meta-analysis and systematic review. Blood Rev. 2018;32:192–202.

    Article  Google Scholar 

  14. 14.

    Baron F, Labopin M, Ruggeri A, Mohty M, Sanz G, Milpied N, et al. Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood-a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. J Hematol Oncol. 2015;8:107.

    Article  Google Scholar 

  15. 15.

    Balligand L, Galambrun C, Sirvent A, Roux C, Pochon C, Bruno B, et al. Single-unit versus double-unit umbilical cord blood transplantation in children and young adults with residual leukemic disease. Biol Blood Marrow Transpl. 2019;25:734–42.

    Article  Google Scholar 

  16. 16.

    Fares I, Chagraoui J, Gareau Y, Gingras S, Ruel R, Mayotte N, et al. Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science. 2014;345:1509–12.

    CAS  Article  Google Scholar 

  17. 17.

    Fares I, Chagraoui J, Lehnertz B, MacRae T, Mayotte N, Tomellini E, et al. EPCR expression marks UM171-expanded CD34(+) cord blood stem cells. Blood 2017;129:3344–51.

    CAS  Article  Google Scholar 

  18. 18.

    van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, et al. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019;3:1858–67.

    Article  Google Scholar 

  19. 19.

    Macmillan ML, Blazar BR, DeFor TE, Wagner JE. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transpl. 2009;43:447–54.

    CAS  Article  Google Scholar 

  20. 20.

    Carrancio S, Romo C, Ramos T, Lopez-Holgado N, Muntion S, Prins HJ, et al. Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment. Cell Transpl. 2013;22:1171–83.

    CAS  Article  Google Scholar 

  21. 21.

    Hagglund H, Ringden O, Agren B, Wennberg L, Remberger M, Rundquist L, et al. Intraosseous compared to intravenous infusion of allogeneic bone marrow. Bone Marrow Transpl. 1998;21:331–5.

    CAS  Article  Google Scholar 

  22. 22.

    Brunstein CG, Barker JN, Weisdorf DJ, Defor TE, McKenna D, Chong SY, et al. Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units. Bone Marrow Transpl. 2009;43:935–40.

    CAS  Article  Google Scholar 

  23. 23.

    Frassoni F, Gualandi F, Podesta M, Raiola AM, Ibatici A, Piaggio G, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol. 2008;9:831–9.

    CAS  Article  Google Scholar 

  24. 24.

    Frassoni F, Varaldo R, Gualandi F, Bacigalupo A, Sambuceti G, Sacchi N, et al. The intra-bone marrow injection of cord blood cells extends the possibility of transplantation to the majority of patients with malignant hematopoietic diseases. Best Pr Res Clin Haematol. 2010;23:237–44.

    Article  Google Scholar 

  25. 25.

    Rocha V, Labopin M, Ruggeri A, Podesta M, Gallamini A, Bonifazi F, et al. Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies. Transplantation 2013;95:1284–91.

    Article  Google Scholar 

  26. 26.

    Bonifazi F, Dan E, Labopin M, Sessa M, Guadagnuolo V, Ferioli M, et al. Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study. Bone Marrow Transpl. 2019;54:717–25.

    CAS  Article  Google Scholar 

  27. 27.

    Saglio F, Berger M, Vassallo E, Nesi F, Gunetti M, Fazio L, et al. Intrabone cord blood hematopoietic stem cell transplantation in a subset of very high-risk pediatric patients: a safety and feasibility pilot study. J Pediatr Hematol Oncol. 2012;34:359–63.

    Article  Google Scholar 

  28. 28.

    Rubinstein P, Dobrila L, Rosenfield RE, Adamson JW, Migliaccio G, Migliaccio AR, et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA. 1995;92:10119–22.

    CAS  Article  Google Scholar 

  29. 29.

    Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl. 1995;15:825–8.

    CAS  Google Scholar 

  30. 30.

    Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945–56.

    Article  Google Scholar 

  31. 31.

    NIH National Cancer Institute. Common terminology criteria for adverse events (CTCAE). 2018. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm

  32. 32.

    Ruggeri A, Volt F, Locatelli F, Michel G, Diaz de Heredia C, Abecasis M, et al. Unrelated cord blood transplantation for acute leukemia diagnosed in the first year of life: outcomes and risk factor analysis. Biol Blood Marrow Transpl. 2017;23:96–102.

    Article  Google Scholar 

  33. 33.

    Chen Y, Xu L, Liu D, Chen H, Zhang X, Han W, et al. Comparative outcomes between cord blood transplantation and bone marrow or peripheral blood stem cell transplantation from unrelated donors in patients with hematologic malignancies: a single-institute analysis. Chin Med J. 2013;126:2499–503.

    CAS  PubMed  Google Scholar 

  34. 34.

    Hayashi H, Volt F, Sanz J, Petersen E, Dhedin N, Hough R, et al. Myeloablative unrelated cord blood transplantation in adolescents and young adults with acute leukemia. Biol Blood Marrow Transpl. 2019;25:2438–46.

    CAS  Article  Google Scholar 

  35. 35.

    de Koning C, Admiraal R, Nierkens S, Boelens JJ. Immune reconstitution and outcomes after conditioning with anti-thymocyte-globulin in unrelated cord blood transplantation; the good, the bad, and the ugly. Stem Cell Investig. 2017;4:38.

    Article  Google Scholar 

  36. 36.

    Admiraal R, van Kesteren C, Jol-van der Zijde CM, Lankester AC, Bierings MB, Egberts TCG, et al. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol. 2015;2:e194–203.

    Article  Google Scholar 

  37. 37.

    Charrier E, Cordeiro P, Brito R-M, Mezziani S, Herblot S, Le Deist F, et al. Reconstitution of maturating and regulatory lymphocyte subsets after cord blood and BMT in children. Bone Marrow Transpl. 2013;48:376–82.

    CAS  Article  Google Scholar 

  38. 38.

    Page KM, Labopin M, Ruggeri A, Michel G, Diaz de Heredia C, O’Brien T, et al. Factors associated with long-term risk of relapse after unrelated cord blood transplantation in children with acute lymphoblastic leukemia in remission. Biol Blood Marrow Transpl. 2017;23:1350–8.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Henrique Bittencourt.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Vairy, S., Louis, I., Vachon, MF. et al. Intrabone infusion for allogeneic umbilical cord blood transplantation in children. Bone Marrow Transplant (2021). https://doi.org/10.1038/s41409-021-01275-0

Download citation

Search

Quick links